One of World's Leading Veterinary Pathologists, Dr. James Moe, Appointed to TissueInformatics Board of Directors.

Business Editors/Health/Medical Writers

PITTSBURGH--(BUSINESS WIRE)--Oct. 21, 2003

TissueInformatics.Inc -- "The Tissue Information Company(R)"

TissueInformatics.Inc (www.TissueInformatics.com) announced today that Dr. James Moe, DVM, Ph.D. has been appointed to the company's Board of Directors.

Dr. Moe is one of the world's leading board-certified veterinary pathologists.

Dr. Moe has held many key positions in his 35 year career. Most recently Dr. Moe was the Vice President of Global Toxicology, Metabolism and Laboratory Animal Medicine for Pharmacia Corporation (Pfizer Inc.) where he led a global staff of approximately 700 employees in 6 R&D sites around the world. In his long standing role at Pharmacia, Dr. Moe held senior corporate responsibility for all aspects of preclinical drug safety, metabolism and pharmacokinetics contributions to the discovery, development and post-marketing testing of pharmaceutical products for the entire Pharmacia portfolio. Under his leadership, the Pharmacia Investigative and Predictive Toxicology capability in Pharmacia was expanded to its current position as one of the recognized industry leaders.

"After a long career in Veterinary Pathology, I am pleased to join TissueInformatics Board of Directors. TissueInformatics exceptional expertise in automated tissue analysis, leading edge technology, senior experienced management team and insightful vision, have led me to conclude that they will truly dominate as the World's Automated Pathology Company. I look forward to providing my experience and guidance as a Veterinary Pathologist to help them succeed." said Dr. James Moe.

Prior to Pharmacia, Dr. Moe held a series of scientific and leadership roles in Department of Defense research laboratories, culminating as Director of Pathology, Walter Reed Army Institute of Research, Washington, DC, where he led research activities and directed a post-graduate residency program in veterinary pathology. Dr. Moe's scientific interests in infectious diseases and drug safety research led to his appointment as a vaccine safety consultant for the World Health Organization and the Rockefeller Foundation, with activities focused in Thailand and China.

Dr. Moe graduated from the University of Minnesota, College of Veterinary Medicine in 1964. Following this, he achieved board certification as a veterinary pathologist in 1973 and received a PhD degree in Comparative Pathology in 1978 from the University of California, Davis, School of Veterinary Medicine, the largest veterinary school in the nation.

Dr. Moe continues his active role in several scientific and professional organizations. He has held leadership roles in the American College of Veterinary Pathologists as a member of the Governing Council, Chairperson of the Examination Committee as well as Vice President and President. Since 1989 he has been a member of the Preclinical Safety Steering Committee of the Pharmaceutical Research and Manufacturers Association, and represented this organization as a Safety Pharmacology topic leader in the Fifth International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals.

Funded by notable investors such as the Aurora Funds, Birchmere Ventures, the Future Fund, Informax, Manulife Financial, Motorola, Smithfield Trust and Techno Venture Management (TVM), TissueInformatics accelerates the drug discovery process by providing a broad range of automated pathology software, tissue analysis services, and drug target discovery solutions to the pharmaceutical, biotechnology and CRO industries.

Statements in this press release that are not strictly historical are "forward-looking" statements, which involve a high degree of risk and uncertainty. Such statements are only predictions, and the actual events or results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to differences include, but are not limited to, risks associated with TissueInformatics.Inc's (the "Company's") dependence upon the creation of strategic alliances with providers for complementary services and products and the need to keep pace with rapid technological change, the Company's dependence for future revenues on its ability to increase sales of its tissue imaging and analysis applications, the development and availability of competitive products or technologies, and the Company's dependence on patents and its ability to defend its intellectual property rights. The Company specifically disclaims any intention or duty to update any forward-looking statements, and these statements represent the Company's current outlook as of the date given.